Lupin Manufacturing Solutions and PolyPeptide announce strategic alliance to scale global peptide supply chain

Lupin Manufacturing Solutions (LMS), a subsidiary of global pharma major Lupin Limited, has announced a long-term strategic alliance with PolyPeptide Group AG, a specialised, global CDMO for peptide-based active pharmaceutical ingredients.

This collaboration aims to enhance supply chain resilience, improve operational efficiency, and accelerate readiness for the rapidly expanding global peptides market. It also advances next-generation peptide therapeutics, including those for metabolics, supporting the long-term strategic growth of both organisations.

As part of the alliance, both companies will work towards expanding sourcing options and fortifying peptide supply chains to meet rising global demand for peptide APIs, including for metabolic disease therapies; integrating procurement and supply planning; and ensuring unwavering quality and reliability and delivering superior service globally

This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets, while enhancing PolyPeptide’s position as a trusted CDMO partner.

Dr Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions, said, “As peptide-based therapies continue to transform the treatment landscape for metabolic and other chronic conditions, LMS is committed to ensuring reliable access to specialised materials that support large-scale commercial production. This underscores our mission to establish secure, agile, and future-ready supply pathways for innovators worldwide.”

"Reliability is a competitive advantage in our industry. Working with Lupin Manufacturing Solutions gives us the flexibility and supply chain depth needed to support growing customer demand, including preparations for large-scale metabolics,” said Stéphane Varray, Chief Commercial Officer, PolyPeptide.